Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.56) by 33.93 percent. This is a 63 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $1.46 million which beat the analyst consensus estimate of $1.14 million by 27.72 percent. This is a 17.42 percent increase over sales of $1.24 million the same period last year.